In Science this week: single-cell tools named Breakthrough of the Year winner, differences in gut microbiome composition and function in people with bowel disease, and more.
In Nature this week: extension to uncultivated virus genome reporting standards, multiplex orthogonal CRISPR-based genome editing approach, and more.
In Nucleic Acids Research this week: updated Aspergillus niger genome annotation, high-throughput sequencing strategy for profiling RNA structure, and more.
The company plans to add 150 to 200 new employees and is quadrupling its space in Pleasanton, California, including a manufacturing site for its microfluidic chips.
The company aims to position its platform as a validation tool for CRISPR-based therapeutics, while continuing to grow in the oncology space.
In a set of new studies, members of an international team mapped gene variation, expression, and regulatory interactions in developing and adult human brains.
The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The life science research tools firm is offering 8,150,000 shares of its common stock at a price of $6.75 per share for gross proceeds of about $55 million.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
In Science this week: single-cell analysis of colorectal cancers finds genome-wide demethylation patterns, and more.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.